Nail Paksoy

Assoc. Prof. Nail Paksoy is an oncologist at Medipol Bahçelievler University Hospital in Turkey. He holds ESMO Board Certification in medical oncology. Dr. Paksoy specializes in systemic therapies, clinical trials, and tumor management.

Specialization and Oncology Approach

Dr. Paksoy treats solid tumors and hematological malignancies. He treats cases of lung, breast, prostate, and gastrointestinal cancers. The doctor also treats conditions like Ewing’s sarcoma and Kaposi sarcoma. He applies protocols including:

• Targeted therapy for lung and breast cancer
• Immunotherapy using agents like Keytruda (Pembrolizumab)
• Lutetium-177 and peptide receptor radionuclide therapy (PRRT) – a molecular therapy that targets specific receptors on cancer cells to deliver radiation
• Chemotherapy for stage 4 cancers
• Hormone therapy for reproductive system tumors

Clinical Trials and Research Focus

Dr. Paksoy serves as a subinvestigator in international clinical trials. He has worked with pharmaceutical companies like ROCHE, Pfizer, and Bayer. His trial experience includes testing Atezolizumab for breast cancer and Lorlatinib for lung cancer. Additionally, he researches treatments for endometrial and ovarian cancers. His clinical work informs his approach to treatment-resistant tumors.

Work Experience

• 2023–present – Associate Professor of Medical Oncology – Medipol Bahçelievler Private Hospital, Istanbul
• 2022–2023 – Medical Oncology Specialist – Tekirdag City Hospital, Turkey
• 2018–2022 – Medical Oncology Fellow – Istanbul University Oncology Institute
• 2017–2018 – Allergy and Immunology Fellow – Istanbul University Istanbul Medical Faculty
• 06/2017–10/2017 – Internal Medicine – Istanbul Gaziosmanpasa Taksim Training and Research Hospital
• 2012–2017 – Internal Medicine Department – Istanbul University Cerrahpaşa Medical Faculty
• 2011–2012 – General Medicine – Erzurum Koprukoyu State Hospital, Turkey

Education and Advanced Training

• 2023 – Medical Oncology Assoc. Prof. – Istanbul Medipol University, Turkey
• 2022 – ESMO Board Certification in Medical Oncology – Paris, France
• 2018–2022 – Medical Oncology Fellowship – Istanbul University Oncology Institute
• 2017–2018 – Allergy-Immunology Fellowship – Istanbul University Istanbul Medical Faculty
• 2012–2017 – Internal Medicine Residency – Istanbul University Cerrahpaşa Medical Faculty
• 2005–2011 – Medical Degree – Sivas Cumhuriyet University Medical Faculty, Turkey

Publications and Scientific Recognition

Dr. Paksoy has authored papers in journals indexed by SCI and SSCI. He frequently presents at ASCO and ESMO congresses. His research appears in Medicine, European Urology Focus, and the Journal of Chemotherapy. Notable publications include:

• "Weekly Paclitaxel in Classic Kaposi Sarcoma" – Medicine
• "Carboplatin Desensitization in Ovarian Carcinoma" – Medicine
• "High-Dose Chemotherapy for Ewing’s Sarcoma" – Medicine
• "Real-Life Efficacy of Osimertinib in Advanced NSCLC" – Journal of Cancer Research and Clinical Oncology
• "Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients" – Turkish Journal of Oncology
• "Multidrug Refractory TFE3(+) Renal Cell Carcinoma" – Journal of Oncology Pharmacy Practice
• "Atezolizumab in Metastatic Urothelial Carcinoma" – European Urology Focus

Professional Memberships

• European Society of Medical Oncology (ESMO)
• Turkish Oncology Group